A Study of Ramucirumab or Icrucumab in Colorectal Cancer

Inclusion Criteria:

Disease progression on an irinotecan-based first-line chemotherapy regimen (ie FOLFIRI or CAPIRI [capecitabine + irinotecan], with or without bevacizumab)
Age ≥ 18 years
Life expectancy of ≥ 6 months
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1 at study entry
Agrees to adequate contraception during the study period and for 12 weeks after the last dose of study medication
Provided signed informed consent

Exclusion Criteria:

Has received prior oxaliplatin-based chemotherapy for locally advanced unresectable or metastatic Colorectal Cancer (CRC) (Prior oxaliplatin-based adjuvant chemotherapy is allowed if the last dose of oxaliplatin was administered > 12 months prior to randomization)
Has documented and/or symptomatic brain or leptomeningeal metastases
Has an ongoing or active infection, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders
On chronic non-topical corticosteroid treatment. A participant discontinuing such treatment > 3 months prior to randomization is eligible
Has uncontrolled or poorly controlled hypertension on a standard regimen of antihypertensive therapy
Has a concurrent active malignancy. A participant with previous history of malignancy is eligible, provided that he/she has been disease free for > 3 years
If female, is pregnant (confirmed by serum beta human chorionic gonadotropin [βHCG] test) or lactating
Has received a prior autologous or allogeneic organ or tissue transplantation
Has undergone major surgery within 28 days prior to randomization
Has had a serious nonhealing wound, ulcer, or bone fracture within 28 days prior to randomization
Has an elective or planned major surgery to be performed during the course of the trial
Has a history of inflammatory bowel disease requiring pharmacological and/or surgical intervention in the 12 months prior to randomization